Woo-Hyoung Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Woo-Hyoung Kang has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Shin Hwang
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
41 shared publications - Gi-Won Song
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
32 shared publications - Deok-Bog Moon
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
31 shared publications - Chul-Soo Ahn
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
29 shared publications - Dong-Hwan Jung
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
29 shared publications - Tae-Yong Ha
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
29 shared publications
Latest Publications
- 27 October 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplantation: Growth From Novice to Maturity
BACKGROUND:Biliary reconstruction is the most technically demanding step in living donor liver transplantation (LDLT), yet how a single surgeon’s technique matures in the early career, and how this relates to clinical outcomes, remains incompletely characterized. This study evaluated whether the stepwise evolution of surgical technique was associated with a lower anastomotic biliary stricture (BS) rate. MATERIAL AND METHODS:We retrospectively analyzed 382 consecutive right-lobe LDLTs with single-surgeon duct-to-duct biliary anastomosis performed between April 2020 and April 2024. Cases were grouped into 3 equal, consecutive time intervals (approximately 16 months each), and cumulative sum (CUSUM) analysis was applied to the learning trajectory. Independent risk factors for BS were identified by multivariable logistic regression, with separate models for surgical period and post-transition-point status. RESULTS:BS rates decreased across periods from 14.4% to 10.1% to 5.1% (P trend=0.016). CUSUM identified a primary transition at case 33, ending the initial trial-and-error phase and coinciding with adoption of well-vascularized distal recipient duct selection, and a secondary inflection at case 210 coinciding with eversion-overlap anastomosis with hilar plate anchoring. Portal vein stenting (OR 6.515, P=0.004) and ABO-incompatible transplantation (OR 2.462, P=0.016) were independent risk factors. After adjustment, surgical period (OR 0.596, P=0.027) and post-case-33 status (OR 0.291, P=0.010) remained associated with lower BS odds. CONCLUSIONS:In this single-surgeon cohort, the stepwise evolution of surgical technique was associated with a progressive reduction in BS rates, alongside the cumulative standardization of fundamental principles, but a concurrently evolving case mix precludes attribution to technique alone.
- 27 October 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplantation: Growth From Novice to Maturity
BACKGROUND:Biliary reconstruction is the most technically demanding step in living donor liver transplantation (LDLT), yet how a single surgeon’s technique matures in the early career, and how this relates to clinical outcomes, remains incompletely characterized. This study evaluated whether the stepwise evolution of surgical technique was associated with a lower anastomotic biliary stricture (BS) rate. MATERIAL AND METHODS:We retrospectively analyzed 382 consecutive right-lobe LDLTs with single-surgeon duct-to-duct biliary anastomosis performed between April 2020 and April 2024. Cases were grouped into 3 equal, consecutive time intervals (approximately 16 months each), and cumulative sum (CUSUM) analysis was applied to the learning trajectory. Independent risk factors for BS were identified by multivariable logistic regression, with separate models for surgical period and post-transition-point status. RESULTS:BS rates decreased across periods from 14.4% to 10.1% to 5.1% (P trend=0.016). CUSUM identified a primary transition at case 33, ending the initial trial-and-error phase and coinciding with adoption of well-vascularized distal recipient duct selection, and a secondary inflection at case 210 coinciding with eversion-overlap anastomosis with hilar plate anchoring. Portal vein stenting (OR 6.515, P=0.004) and ABO-incompatible transplantation (OR 2.462, P=0.016) were independent risk factors. After adjustment, surgical period (OR 0.596, P=0.027) and post-case-33 status (OR 0.291, P=0.010) remained associated with lower BS odds. CONCLUSIONS:In this single-surgeon cohort, the stepwise evolution of surgical technique was associated with a progressive reduction in BS rates, alongside the cumulative standardization of fundamental principles, but a concurrently evolving case mix precludes attribution to technique alone.
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-15
Prediction of Post-Resection Prognosis of HCC According to AFP-PIVKA-II (AP) Score as a Simplified Biomarker of ADV Score: A Validation Analysis Using Korea Liver Cancer Registry Database
Background: A simplified prognostic model, the AFP–PIVKA-II (AP) score, was developed to predict outcomes after resection of hepatocellular carcinoma (HCC). Unlike the conventional ADV score, it relies only on serum biomarkers (AFP and PIVKA-II), excluding tumor size. Methods: This study included 2257 patients who underwent liver resection for HCC, using data from the Korea Liver Cancer Registry (2015– 2022). The AP score’s ability to predict overall survival (OS) and microvascular invasion (MVI) was evaluated and compared with radiologic and pathologic ADV scores. Results: Median preoperative AFP and PIVKA-II levels were 9.2 ng/mL and 62 mAU/mL. Increasing AP scores showed consistent association with worse OS (p < 0.001). Kaplan–Meier survival analyses using 1.0 log-, 2.0 log-, and 4.0 log-interval groupings consistently demonstrated a stepwise decline in OS with increasing AP score (all p < 0.001). At 4.0 log intervals, Harrell’s c-indices for OS prediction were 0.604 (AP score), 0.681 (radiologic ADV score), and 0.677 (pathologic ADV score). For MVI prediction, the areas under the ROC curve values were 0.705, 0.733, and 0.741, respectively. Although ADV score-based models performed better overall, the AP score showed acceptable predictive ability for post-resection patient survival. Conclusion: The AP score is a simple, biomarker-based tool for estimating survival after HCC resection. While less accurate than ADV score models, its convenience supports use in settings requiring rapid assessment.
- 1 September 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-15
Open AccessPrediction of Post-Resection Prognosis of HCC According to AFP-PIVKA-II (AP) Score as a Simplified Biomarker of ADV Score: A Validation Analysis Using Korea Liver Cancer Registry Database
Background: A simplified prognostic model, the AFP–PIVKA-II (AP) score, was developed to predict outcomes after resection of hepatocellular carcinoma (HCC). Unlike the conventional ADV score, it relies only on serum biomarkers (AFP and PIVKA-II), excluding tumor size. Methods: This study included 2257 patients who underwent liver resection for HCC, using data from the Korea Liver Cancer Registry (2015– 2022). The AP score’s ability to predict overall survival (OS) and microvascular invasion (MVI) was evaluated and compared with radiologic and pathologic ADV scores. Results: Median preoperative AFP and PIVKA-II levels were 9.2 ng/mL and 62 mAU/mL. Increasing AP scores showed consistent association with worse OS (p < 0.001). Kaplan–Meier survival analyses using 1.0 log-, 2.0 log-, and 4.0 log-interval groupings consistently demonstrated a stepwise decline in OS with increasing AP score (all p < 0.001). At 4.0 log intervals, Harrell’s c-indices for OS prediction were 0.604 (AP score), 0.681 (radiologic ADV score), and 0.677 (pathologic ADV score). For MVI prediction, the areas under the ROC curve values were 0.705, 0.733, and 0.741, respectively. Although ADV score-based models performed better overall, the AP score showed acceptable predictive ability for post-resection patient survival. Conclusion: The AP score is a simple, biomarker-based tool for estimating survival after HCC resection. While less accurate than ADV score models, its convenience supports use in settings requiring rapid assessment.
- 23 July 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Bilateral duct-to-duct anastomosis in dual left graft living donor liver transplantation: Bile duct position assessment after graft procurement and perfusion—A retrospective cohort study
In adult dual left liver graft living donor liver transplantation (LDLT), composite rotation of the right-sided graft alters the bile duct–portal vein relationship, making bilateral duct-to-duct (D-D) reconstruction technically challenging. Although bilateral D-D preserves endoscopic access and avoids enteric reconstruction, no structured intraoperative strategy has been established. From 36 consecutive dual left graft LDLT procedures, we propose a practical approach based on bile duct–portal vein positional patterns and a 2-stage intraoperative assessment. Bilateral D-D was achieved in 26 patients (72.2%) without bile leak. Biliary stricture occurred in 38.5% and was managed endoscopically in 88.9% without surgical reintervention. Portal vein narrowing developed in 8 patients (22.2%), most often when the right graft bile duct lay deeply posterior to the portal vein after rotation (55.6% vs. 11.1%–12.5% in other patterns). Among patients with narrowing and long-term follow-up, all 4 conservatively managed grafts developed right graft atrophy, whereas none of the 3 managed with intraoperative portal vein stenting did; no mortality was attributable to narrowing. Bilateral D-D is therefore achievable when guided by intraoperative assessment of the bile duct–portal vein relationship after composite rotation: hepaticojejunostomy should be performed without hesitation in unfavorable configurations, and intraoperative portal vein stenting should be considered selectively when narrowing is detected. In carefully selected patients, bilateral D-D is a feasible strategy that preserves endoscopic access; these single-center observations are exploratory and warrant prospective validation.
- 23 July 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Bilateral duct-to-duct anastomosis in dual left graft living donor liver transplantation: Bile duct position assessment after graft procurement and perfusion—A retrospective cohort study
In adult dual left liver graft living donor liver transplantation (LDLT), composite rotation of the right-sided graft alters the bile duct–portal vein relationship, making bilateral duct-to-duct (D-D) reconstruction technically challenging. Although bilateral D-D preserves endoscopic access and avoids enteric reconstruction, no structured intraoperative strategy has been established. From 36 consecutive dual left graft LDLT procedures, we propose a practical approach based on bile duct–portal vein positional patterns and a 2-stage intraoperative assessment. Bilateral D-D was achieved in 26 patients (72.2%) without bile leak. Biliary stricture occurred in 38.5% and was managed endoscopically in 88.9% without surgical reintervention. Portal vein narrowing developed in 8 patients (22.2%), most often when the right graft bile duct lay deeply posterior to the portal vein after rotation (55.6% vs. 11.1%–12.5% in other patterns). Among patients with narrowing and long-term follow-up, all 4 conservatively managed grafts developed right graft atrophy, whereas none of the 3 managed with intraoperative portal vein stenting did; no mortality was attributable to narrowing. Bilateral D-D is therefore achievable when guided by intraoperative assessment of the bile duct–portal vein relationship after composite rotation: hepaticojejunostomy should be performed without hesitation in unfavorable configurations, and intraoperative portal vein stenting should be considered selectively when narrowing is detected. In carefully selected patients, bilateral D-D is a feasible strategy that preserves endoscopic access; these single-center observations are exploratory and warrant prospective validation.
- Open Access
- 7 July 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Outcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective study
Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0010
- 7 July 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Open AccessOutcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective study
Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0010
- Open Access
- 12 March 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
- Vol. 6 (1) , 25-32
AFP-PIVKA-II score as a simplified quantifiable surrogate biomarker for hepatocellular carcinoma recurrence following living donor liver transplantation
Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, Sung-Gyu Lee. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.25.0024
- 12 March 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
- Vol. 6 (1) , 25-32
Open AccessAFP-PIVKA-II score as a simplified quantifiable surrogate biomarker for hepatocellular carcinoma recurrence following living donor liver transplantation
Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, Sung-Gyu Lee. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.25.0024
- Open Access
- 24 February 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e950997
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma
BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be an incidental finding in liver explants following liver transplantation (LT). This study aimed to evaluate the long-term post-transplant outcomes of patients with ICC. MATERIAL AND METHODS From 2003 to 2022, 25 patients with ICC were identified among 6,611 adult LT recipients through institutional database search. RESULTS The incidence of ICC among adult LT recipients was 0.4%. All cases were incidental findings in explanted livers. The mean ICC tumor size was 2.7±1.6 cm, and 22 patients had single ICC lesion. Concurrent second liver malignancies were found in 10 patients (40%): hepatocellular carcinoma (HCC) in 9 and combined HCC-cholangiocarcinoma in one. The 5-year all-type tumor recurrence (TR) and overall survival (OS) rates were 72.0% and 47.0%, respectively. The presence of second primary cancer had no significant impact on TR (P=0.832) or OS (P=0.533). Similarly, ICC tumor stage did not significantly affect TR (P=0.394) or OS (P=0.395). Among 15 patients with ICC alone, 11 (73.3%) experienced ICC recurrence. Of the 10 patients with concurrent malignancies, 7 (70.0%) experienced all-type TR: 5 with HCC and 2 with ICC. Notably, the 5-year ICC recurrence and OS rates in 5 patients with very early-stage ICC and no HCC recurrence were 20.0% and 80.0%, respectively. CONCLUSIONS ICC is a rare incidental finding in LT recipients, often coexisting with concurrent second liver malignancy. Overall prognosis following LT for ICC remains poor, except for those with very early-stage disease. Because all incidences of TR occurred within 5 years after transplant, rigorous surveillance is essential during this period.
- 24 February 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e950997
Open AccessSurvival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma
BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be an incidental finding in liver explants following liver transplantation (LT). This study aimed to evaluate the long-term post-transplant outcomes of patients with ICC. MATERIAL AND METHODS From 2003 to 2022, 25 patients with ICC were identified among 6,611 adult LT recipients through institutional database search. RESULTS The incidence of ICC among adult LT recipients was 0.4%. All cases were incidental findings in explanted livers. The mean ICC tumor size was 2.7±1.6 cm, and 22 patients had single ICC lesion. Concurrent second liver malignancies were found in 10 patients (40%): hepatocellular carcinoma (HCC) in 9 and combined HCC-cholangiocarcinoma in one. The 5-year all-type tumor recurrence (TR) and overall survival (OS) rates were 72.0% and 47.0%, respectively. The presence of second primary cancer had no significant impact on TR (P=0.832) or OS (P=0.533). Similarly, ICC tumor stage did not significantly affect TR (P=0.394) or OS (P=0.395). Among 15 patients with ICC alone, 11 (73.3%) experienced ICC recurrence. Of the 10 patients with concurrent malignancies, 7 (70.0%) experienced all-type TR: 5 with HCC and 2 with ICC. Notably, the 5-year ICC recurrence and OS rates in 5 patients with very early-stage ICC and no HCC recurrence were 20.0% and 80.0%, respectively. CONCLUSIONS ICC is a rare incidental finding in LT recipients, often coexisting with concurrent second liver malignancy. Overall prognosis following LT for ICC remains poor, except for those with very early-stage disease. Because all incidences of TR occurred within 5 years after transplant, rigorous surveillance is essential during this period.
- Open Access
- 18 February 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 39, 16021
Long-Term Renal Outcomes Following Left Renal Vein Ligation Versus Direct Splenorenal Shunt Ligation in Living Donor Liver Transplantation: A 10-Year Single-Center Study
In living donor liver transplantation (LDLT), large splenorenal shunts (SRS) can divert portal inflow and negatively affect graft function due to portal steal syndrome. Direct SRS ligation (SRSL) and left renal vein ligation (LRVL) are used to prevent this complication; however, the long-term renal impact of LRVL remains unclear, particularly in recipients requiring nephrotoxic immunosuppression. We retrospectively analyzed adult LDLT recipients with large SRS (>1 cm) and normal baseline renal function who underwent SRSL (n = 120) or LRVL (n = 74). Patient and graft survival, serial renal function profiles, and tacrolimus trough levels were evaluated. Survival outcomes were comparable between the two groups. LRVL was more frequently performed in patients with higher preoperative Model for End-Stage Liver Disease (MELD) scores or increased transfusion requirements. During long-term follow-up, the LRVL group showed a more evident decline in renal function, with persistently higher serum creatinine levels, despite similar tacrolimus exposure. Four recipients in the LRVL group progressed to end-stage renal disease requiring dialysis within 10 years, whereas no dialysis cases occurred following SRSL. Although both strategies are clinically feasible, LRVL demonstrated a stronger association with progressive renal deterioration. These findings suggest that SRSL may be preferred in recipients with renal vulnerability to minimize cumulative renal burden.
- 18 February 2026
- Published by Frontiers Media SA in Transplant International
- Vol. 39, 16021
Open AccessLong-Term Renal Outcomes Following Left Renal Vein Ligation Versus Direct Splenorenal Shunt Ligation in Living Donor Liver Transplantation: A 10-Year Single-Center Study
In living donor liver transplantation (LDLT), large splenorenal shunts (SRS) can divert portal inflow and negatively affect graft function due to portal steal syndrome. Direct SRS ligation (SRSL) and left renal vein ligation (LRVL) are used to prevent this complication; however, the long-term renal impact of LRVL remains unclear, particularly in recipients requiring nephrotoxic immunosuppression. We retrospectively analyzed adult LDLT recipients with large SRS (>1 cm) and normal baseline renal function who underwent SRSL (n = 120) or LRVL (n = 74). Patient and graft survival, serial renal function profiles, and tacrolimus trough levels were evaluated. Survival outcomes were comparable between the two groups. LRVL was more frequently performed in patients with higher preoperative Model for End-Stage Liver Disease (MELD) scores or increased transfusion requirements. During long-term follow-up, the LRVL group showed a more evident decline in renal function, with persistently higher serum creatinine levels, despite similar tacrolimus exposure. Four recipients in the LRVL group progressed to end-stage renal disease requiring dialysis within 10 years, whereas no dialysis cases occurred following SRSL. Although both strategies are clinically feasible, LRVL demonstrated a stronger association with progressive renal deterioration. These findings suggest that SRSL may be preferred in recipients with renal vulnerability to minimize cumulative renal burden.
- Open Access
- 27 January 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e951216
Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience
BACKGROUND The availability of homologous vein allografts is limited. Therefore, prosthetic vascular grafts can be used as alternatives for middle hepatic vein (MHV) reconstruction during living-donor liver transplantation (LDLT). This study evaluated the short- and long-term patency of MHV reconstructions using Hemashield vascular grafts and assessed their effect on post-transplant survival. MATERIAL AND METHODS This retrospective observational study included 149 adult LDLT recipients who underwent MHV reconstruction using Hemashield grafts at a single institution. Graft patency and survival outcomes were assessed over long-term follow-up. RESULTS The mean recipient age was 56.2±7.7 years, and the mean graft-to-recipient weight ratio was 1.06±0.25. V5 reconstruction was achieved through single, double, and triple anastomoses in 111, 32, and 2 patients, respectively. V8 reconstruction in 116, 20, and one patient was achieved through single, double, and triple anastomoses, respectively. In 100 and 49 cases, we used Hemashield grafts with diameters of 10 mm and 12 mm, respectively. Three patients (2.0%) developed early thrombosis that necessitated stent placement. The cumulative conduit occlusion-free survival rates were 81.0% at 3 months, 57.9% at 1 year, 48.7% at 3 years, and 43.8% at 5 years. Overall patient survival rates were 95.3% at 1 year, 89.1% at 3 years, and 85.7% at 5 years. No cases of graft migration or conduit-related infection were identified. CONCLUSIONS MHV reconstruction using Hemashield grafts demonstrated acceptable short- and long-term patency, with no migration or infection. These findings support the use of Hemashield grafts as a reliable and effective prosthetic option for MHV reconstruction during LDLT.
- 27 January 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e951216
Open AccessLong-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience
BACKGROUND The availability of homologous vein allografts is limited. Therefore, prosthetic vascular grafts can be used as alternatives for middle hepatic vein (MHV) reconstruction during living-donor liver transplantation (LDLT). This study evaluated the short- and long-term patency of MHV reconstructions using Hemashield vascular grafts and assessed their effect on post-transplant survival. MATERIAL AND METHODS This retrospective observational study included 149 adult LDLT recipients who underwent MHV reconstruction using Hemashield grafts at a single institution. Graft patency and survival outcomes were assessed over long-term follow-up. RESULTS The mean recipient age was 56.2±7.7 years, and the mean graft-to-recipient weight ratio was 1.06±0.25. V5 reconstruction was achieved through single, double, and triple anastomoses in 111, 32, and 2 patients, respectively. V8 reconstruction in 116, 20, and one patient was achieved through single, double, and triple anastomoses, respectively. In 100 and 49 cases, we used Hemashield grafts with diameters of 10 mm and 12 mm, respectively. Three patients (2.0%) developed early thrombosis that necessitated stent placement. The cumulative conduit occlusion-free survival rates were 81.0% at 3 months, 57.9% at 1 year, 48.7% at 3 years, and 43.8% at 5 years. Overall patient survival rates were 95.3% at 1 year, 89.1% at 3 years, and 85.7% at 5 years. No cases of graft migration or conduit-related infection were identified. CONCLUSIONS MHV reconstruction using Hemashield grafts demonstrated acceptable short- and long-term patency, with no migration or infection. These findings support the use of Hemashield grafts as a reliable and effective prosthetic option for MHV reconstruction during LDLT.
- Open Access
- 19 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11840-11852
ADV score plus FDG-PET as preoperative predictors of post-resection prognosis in patients with hepatocellular carcinoma ≥10 cm: a retrospective cohort validation study
Background: The ADV score, calculated by multiplying α-fetoprotein, des-γ-carboxy prothrombin, and tumor volume (TV), is a surrogate marker for post-resection prognosis in hepatocellular carcinoma (HCC). 2- 18 F-fluoro-2-deoxy- d -glucose (FDG) positron emission tomography (PET) reflects the tumor biology. This study aimed to validate prognostic prediction models (PPMs) that combined the ADV score and FDG-PET in patients undergoing resection for large HCC tumors (≥10 cm). Methods: Of the 7905 patients who underwent resection for HCC between 2009 and 2018, 412 with solitary tumors ≥10 cm were analyzed. Results: The median pathological and radiological tumor diameters and TVs were 12.0 and 11.0 cm and 575 and 696 mL, respectively. The median values of pathological, radiological and volumetric TVs converged at 2.8log mL; therefore, radiological TV was selected. At 1, 3, 5, and 10 years, the tumor recurrence (TR) rates were 60.7, 72.2, 76.6, and 85.1%, respectively, and the overall survival (OS) rates were 77.7, 56.5, 48.2, and 35.5%, respectively. Independent risk factors for TR included viral hepatitis, hypermetabolic PET, microvascular invasion (MVI), and satellite nodules. Hypermetabolic PET, MVI, satellite nodules, and cirrhosis were significant predictive factors of OS. The ADV scores, expressed in 2.0log-intervals, showed a clear prognostic separation of TR and OS. Combining the ADV score with FDG-PET activity further improved the predictive accuracy, leading to two PPMs: a two-tiered model (hypermetabolic PET with ADV ≥7.0log vs. others) and a four-tiered model (isometabolic PET and hypermetabolic PET stratified by ADV <7.0log, ≥7.0log and <11.0log, and ≥11.0log). Conclusions: These two PPMs reliably predicted post-resection outcomes in patients with large HCC, making them useful tools for guiding surgical decisions and postoperative surveillance in high-risk patients.
- 19 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (5) , 11840-11852
Open AccessADV score plus FDG-PET as preoperative predictors of post-resection prognosis in patients with hepatocellular carcinoma ≥10 cm: a retrospective cohort validation study
Background: The ADV score, calculated by multiplying α-fetoprotein, des-γ-carboxy prothrombin, and tumor volume (TV), is a surrogate marker for post-resection prognosis in hepatocellular carcinoma (HCC). 2- 18 F-fluoro-2-deoxy- d -glucose (FDG) positron emission tomography (PET) reflects the tumor biology. This study aimed to validate prognostic prediction models (PPMs) that combined the ADV score and FDG-PET in patients undergoing resection for large HCC tumors (≥10 cm). Methods: Of the 7905 patients who underwent resection for HCC between 2009 and 2018, 412 with solitary tumors ≥10 cm were analyzed. Results: The median pathological and radiological tumor diameters and TVs were 12.0 and 11.0 cm and 575 and 696 mL, respectively. The median values of pathological, radiological and volumetric TVs converged at 2.8log mL; therefore, radiological TV was selected. At 1, 3, 5, and 10 years, the tumor recurrence (TR) rates were 60.7, 72.2, 76.6, and 85.1%, respectively, and the overall survival (OS) rates were 77.7, 56.5, 48.2, and 35.5%, respectively. Independent risk factors for TR included viral hepatitis, hypermetabolic PET, microvascular invasion (MVI), and satellite nodules. Hypermetabolic PET, MVI, satellite nodules, and cirrhosis were significant predictive factors of OS. The ADV scores, expressed in 2.0log-intervals, showed a clear prognostic separation of TR and OS. Combining the ADV score with FDG-PET activity further improved the predictive accuracy, leading to two PPMs: a two-tiered model (hypermetabolic PET with ADV ≥7.0log vs. others) and a four-tiered model (isometabolic PET and hypermetabolic PET stratified by ADV <7.0log, ≥7.0log and <11.0log, and ≥11.0log). Conclusions: These two PPMs reliably predicted post-resection outcomes in patients with large HCC, making them useful tools for guiding surgical decisions and postoperative surveillance in high-risk patients.
- Open Access
- 9 January 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 40 (2) , 243-253
Prognostic validation of ADV and MoRAL scores for hepatocellular carcinoma recurrence following living donor liver transplantation: a long-term follow-up study
Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0063
- 9 January 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 40 (2) , 243-253
Open AccessPrognostic validation of ADV and MoRAL scores for hepatocellular carcinoma recurrence following living donor liver transplantation: a long-term follow-up study
Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0063